A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Evofosfamide (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 15 Aug 2017 Status changed from active, no longer recruiting to discontinued due to lack of enrolment.
- 10 Jun 2017 Biomarkers information updated
- 22 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.